Schwalen, S.
16  Ergebnisse:
Personensuche X
?
2

Galantamine treatment in Alzheimer's disease with cerebrova..:

Erkinjuntti, T. ; Gauthier, S. ; Bullock, R....
Journal of Psychopharmacology.  22 (2008)  7 - p. 761-768 , 2008
 
?
4

Time course of adverse events most commonly associated with..:

Láinez, M. J. A. ; Freitag, F. G. ; Pfeil, J....
European Journal of Neurology.  14 (2007)  8 - p. 900-906 , 2007
 
?
5

P4.026 Galantamine prolonged-release formulation permits on..:

Brodaty, H. ; Schwalen, S. ; Gold, M.
European Neuropsychopharmacology.  14 (2004)  - p. S333-S334 , 2004
 
?
 
?
7

Significant improvements in symptoms in patients with 'adva..:

Kurz, A. ; Schwalen, S.
European Neuropsychopharmacology.  11 (2001)  - p. S325-S326 , 2001
 
?
8

Galantamine is effective in older patients with Alzheimer's..:

Marcusson, J. ; Schwalen, S.
European Neuropsychopharmacology.  11 (2001)  - p. S326 , 2001
 
?
9

Sleep related breathing disturbances and nocturnal akinesia..:

Schwalen, S. ; Leclaire, J. ; Rechlin, M..
European Journal of Neurology.  4 (1997)  4 - p. 360-364 , 1997
 
?
11

Long-Term Response to Galantamine in Relation to Short-Term..:

Kavanagh, S ; Howe, I ; Brashear, H R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182415.  , 2011
 
?
15

antiSMASH 4.0-improvements in chemistry prediction and gene..:

Blin, Kai ; Wolf, Thomas ; Chevrette, Marc G...
https://orbit.dtu.dk/en/publications/b46050ea-65f7-429d-a79a-53ba79fb896a.  , 2017
 
1-15